The Limited Times

Now you can see non-English news...

AstraZeneca vaccine is 'highly effective' against Delta and Beta variants


The pharmaceutical company announced that a dose is 87% effective in the event of 'hospitalization or death'.

07/23/2021 10:26 AM

  • Clarí

  • Society

Updated 07/23/2021 11:15 AM




is "

highly effective

" with a dose to prevent serious cases of coronavirus and hospitalizations caused by the

Delta and Beta variants

, the Anglo-Swedish pharmaceutical company reported on Friday.

A study carried out in Canada with 69,533 infected with Covid-19, developed between December 2020 and May 2021, indicated that the vaccine is

82% effective with a single dose

, in the face of "hospitalization or death" caused by the

Beta variant

, first identified in South Africa.

Meanwhile, the clinical trial demonstrated an

efficacy of 87%

with a single inoculation against "hospitalization or death" caused by the

Delta variant

, and

90% against the Alpha strain

of the coronavirus,

Of the total number of

people who participated in the study

carried out by the Canadian Immunization Research Network (CIRN), 40,828

(9.7%) were positive

for any

of the variants considered "worrisome"

, while 28,705 (

6.8% ) were infected with other strains

of the coronavirus.

The analysis notes that there was not enough time to report on the effectiveness of the AstraZeneca vaccine after the second dose, although "other studies have shown an increase in efficacy."

"The efficacy of Vaxzevria (brand name) after one dose against hospitalization or death was similar to that of other vaccines tested in the study," AstraZeneca said in a statement.

The executive vice president of R&D of the Anglo-Swedish company, Mene Pangalos, stressed that the vaccine offers "a

high level of protection


against the "most serious forms"

of the coronavirus, even after "a single dose".

"It is essential that we continue to protect as many people as possible in all corners of the world in order to anticipate this deadly virus."

Antibody treatment

AstraZeneca admitted days ago that an antibody treatment it developed does not prevent the coronavirus, since its efficacy in people exposed to the virus has not been proven.

Antibody treatment, called AZD7442, aims to prevent and treat the disease.

However, it did not work.


The trial did not achieve the primary goal of preventing symptomatic cases

of Covid-19 after exposure to the virus," the company explained in an official statement.

The experiment was in phase 3 of development, that is, in large-scale clinical trials to measure its safety and efficacy.

The 1,121 people who participated in the process were adults over 18 years of age who were not vaccinated and who had been exposed to an infected person during the previous eight days.

With information from EFE and AFP


Look also

Russia assures that it will comply with the delivery of vaccines to Argentina, but that the priority is to supply its country

Johnson & Johnson Vaccine May Cause Neurodegenerative Disorders

Source: clarin

All life articles on 2021-07-23

You may like

Trends 24h


© Communities 2019 - Privacy